Market research
CRBP Corbus Pharmaceuticals Holding
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 201M
- P/E ratio
- Not available
- Analyst target
- 34.525
- Dividend yield
- Not available
- Beta
- 2.62
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US21833P3010
- Market cap
- 201M
- P/E ratio
- Not available
- Analyst target
- 34.525
- Dividend yield
- Not available
- Beta
- 2.62
About
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CRBP discussion.
5 years, 4 months ago
Corbus Pharmaceuticals Holdings, Inc is currently in a long term downtrend where the price is trading 5.5% below its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 40.7.
Corbus Pharmaceuticals Holdings, Inc's total revenue sank by 74.4% to $658K since the same quarter in the previous year.
Its net income has increased by 67.6% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.4% to $-18M since the same quarter in the previous year.
Based on the above factors, Corbus Pharmaceuticals Holdings, Inc gets an overall score of 3/5.